PMID- 17288688
OWN - NLM
STAT- MEDLINE
DCOM- 20070315
LR  - 20151119
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 23
IP  - 2
DP  - 2007 Feb
TI  - Quetiapine augmentation of treatment-resistant depression: a comparison with 
      lithium.
PG  - 333-41
AB  - OBJECTIVE: The prevalence of and morbidity associated with treatment-resistant 
      depression has motivated the exploration of treatment alternatives. In this 
      study, quetiapine was compared with lithium in the augmentation of 
      treatment-resistant depression. RESEARCH DESIGN AND METHODS: Open-label, 
      comparative study in 20 patients with major depression who had failed to respond 
      after 4 weeks of treatment with an antidepressant at the maximal recommended 
      dose. Patients were randomised to either lithium or quetiapine in addition to the 
      maximally dosed antidepressant and any other concurrent medications. Lithium was 
      initiated at 600 mg/day; quetiapine was titrated to 400 mg by day 7. RESULTS: 
      Depression, measured by the Hamilton Depression Rating Scale (HAM-D), 
      significantly improved from baseline in both quetiapine (F(1,90) = 25.11, p < 
      0.0001) and lithium (F(1,90) = 34.54, p < 0.0001). The difference in improvement 
      between the two groups began at day 14 and was seen at all timepoints thereafter 
      (p < 0.05), with the quetiapine group showing greater improvement than the 
      lithium group. In the Montgomery-Asberg Depression Rating Scale (MADRS) analysis, 
      the difference between the quetiapine and lithium group was significant from day 
      28 onwards (p < 0.05), with subjects improving more in the quetiapine group than 
      the lithium group. The treatment by week interaction showed a significant 
      difference overall between the two groups (p < 0.0001). The severity of 
      psychomotor retardation showed a significant decrease in the Widlocher 
      Psychomotor Retardation Scale scores in the quetiapine (p < 0.0001) and lithium 
      (p < 0.0001) groups. CONCLUSIONS: In this pilot study, quetiapine was an 
      effective augmenting agent in treatment-resistant depression.
FAU - Doree, Jean-Pierre
AU  - Doree JP
AD  - Centre Hospitalier Pierre Legardeur, Montreal, Quebec, Canada.
FAU - Des Rosiers, Joel
AU  - Des Rosiers J
FAU - Lew, Viviane
AU  - Lew V
FAU - Gendron, Alain
AU  - Gendron A
FAU - Elie, Robert
AU  - Elie R
FAU - Stip, Emmanuel
AU  - Stip E
FAU - Tourjman, S Valerie
AU  - Tourjman SV
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Antidepressive Agents)
RN  - 0 (Dibenzothiazepines)
RN  - 0 (Lithium Compounds)
RN  - 0 (Serotonin Receptor Agonists)
RN  - 2S3PL1B6UJ (Quetiapine Fumarate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antidepressive Agents/administration & dosage/adverse 
      effects/pharmacology/*therapeutic use
MH  - Depressive Disorder/*drug therapy
MH  - Dibenzothiazepines/administration & dosage/adverse 
      effects/pharmacology/*therapeutic use
MH  - Drug Resistance
MH  - Drug Synergism
MH  - Drug Therapy, Combination
MH  - Fatigue/chemically induced
MH  - Female
MH  - Humans
MH  - Lithium Compounds/administration & dosage/adverse 
      effects/pharmacology/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Nausea/chemically induced
MH  - Pilot Projects
MH  - Psychomotor Performance/drug effects
MH  - Quetiapine Fumarate
MH  - Serotonin Receptor Agonists/administration & dosage/adverse 
      effects/pharmacology/therapeutic use
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Tremor/chemically induced
EDAT- 2007/02/10 09:00
MHDA- 2007/03/16 09:00
CRDT- 2007/02/10 09:00
PHST- 2007/02/10 09:00 [pubmed]
PHST- 2007/03/16 09:00 [medline]
PHST- 2007/02/10 09:00 [entrez]
AID - 10.1185/030079906X162809 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2007 Feb;23(2):333-41. doi: 10.1185/030079906X162809.